EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
1 . An isolated antisense oligonucleotide of 20 to 50 nucleotides in length comprising at least 10 consecutive nucleotides of a nucleotide sequence selected from the group consisting of: SEQ ID NOs: 1-7, wherein the oligonucleotide specifically hybridizes to an exon 44 target region of the human dystrophin gene and induces exon 44 skipping, and wherein thymine bases are optionally uracil bases.
2 . The antisense oligonucleotide of claim 1 , comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 and 6.
3 . The antisense oligonucleotide of claim 1 , consisting of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 and 6.
4 . The antisense oligonucleotide of claim 1 , wherein the oligonucleotide does not activate RNase H.
5 . The antisense oligonucleotide of claim 1 , comprising a non-natural backbone.
6 . The antisense oligonucleotide of claim 1 , wherein the sugar moieties of the oligonucleotide backbone are replaced with non-natural moieties.
7 . The antisense oligonucleotide of claim 6 , wherein the non-natural moieties are morpholinos.
8 . The antisense oligonucleotide of claim 1 , wherein the inter-nucleotide linkages of the oligonucleotide backbone are replaced with non-natural inter-nucleotide linkages.
9 . The antisense oligonucleotide of claim 8 , wherein the non-natural inter-nucleotide linkages are modified phosphates.
10 . The antisense oligonucleotide of claim 1 , wherein the sugar moieties of the oligonucleotide backbone are replaced with non-natural moieties and the inter-nucleotide linkages of the oligonucleotide backbone are replaced with non-natural inter-nucleotide linkages.
11 . The antisense oligonucleotide of claim 10 , wherein the non-natural moieties are morpholinos and the non-natural internucleotide linkages are modified phosphates.
12 . The antisense oligonucleotide of claim 11 , wherein the modified phosphates are methyl phosphonates, methyl phosphorothioates, phosphoromorpholidates, phosphoropiperazidates, or phosphoroamidates.
13 . The antisense oligonucleotide of claim 1 , wherein the oligonucleotide is a 2′-O-methyl-oligoribonucleotide.
14 . The antisense oligonucleotide of claim 1 , wherein the oligonucleotide is a peptide nucleic acid.
15 . The antisense oligonucleotide of claim 1 , wherein the oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide.
16 . The antisense oligonucleotide of claim 15 , wherein the oligonucleotide is conjugated to an arginine-rich cell penetrating peptide.
17 . The antisense oligonucleotide of claim 15 , wherein the oligonucleotide is chemically linked to a polyethylene glycol moiety.
18 . An isolated antisense oligonucleotide of 20 to 50 nucleotides in length comprising at least 10 consecutive nucleotides complementary to an exon 44 target region of the human dystrophin gene designated as an annealing site selected from the group consisting of: H44A(−07+17), H44A(−07+20), H44A(−07+22), H44A(+77+101), H44A(+64+91), H44A(+62+89), and H44A(+62+85), wherein the antisense oligonucleotide specifically hybridizes to the annealing site inducing exon 44 skipping.
19 . The antisense oligonucleotide of claim 18 , comprising 25 to 28 nucleotides in length.
20 . The antisense oligonucleotide of claim 18 , wherein the thymine bases are uracil bases.
21 - 42 . (canceled)